Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 13/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.98 |
| ▸ | HTT | P42858 | 5/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.89 |
| ▸ | MEN1 | O00255 | 5/20 | 0.89 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.89 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.89 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.83 |
| ▸ | TSHR | P16473 | 6/20 | 0.83 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.83 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.82 |
| ▸ | GAA | P10253 | 2/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.72 |
| ▸ | MITF | O75030 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497664 | 0.95 | LMNA (0.98) | LMNAKMT2AHTTNPSR1MEN1 | |
| SCHEMBL2474484 | 0.92 | LMNA (0.98) | LMNAKMT2AHTTNPSR1MEN1 | |
| SCHEMBL2496455 | 0.92 | SLC5A2 (1.00) | LMNAKMT2AHTTNPSR1MEN1 | |
| Bromide SCHEMBL940477 | 0.90 | SLC5A2 (0.97) | LMNAKMT2AHTTNPSR1MEN1 | |
| Hydrochloric Acid SCHEMBL29445223 | 0.90 | LMNA (1.00) | LMNAKMT2AHTTNPSR1MEN1 | |
| SCHEMBL2496035 | 0.89 | LMNA (0.89) | LMNAKMT2AHTTNPSR1MEN1 | |
| SCHEMBL13332637 | 0.89 | SLC5A2 (0.86) | LMNAKMT2AHTTNPSR1MEN1 | |
| SCHEMBL2495262 | 0.86 | LMNA (0.91) | LMNAKMT2AHTTNPSR1MEN1 | |
| SCHEMBL14847726 | 0.85 | SLC5A2 (0.86) | LMNAKMT2AHTTNPSR1MEN1 | |
| SCHEMBL2494794 | 0.85 | LMNA (0.98) | LMNAKMT2AHTTNPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373629-B1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-04-10 | — | — | EP | claimed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| EP-2373629-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-12 | — | — | EP | claimed |
| WO-2010067067-A1 | COMPOUNDS FOR TREATING CANCER | EVOTEC AG (DE) | 2010-06-17 | — | — | WO | claimed |
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| EP-2373629-B1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-04-10 | — | — | EP | disclosed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| EP-2373629-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010067067-A1 | COMPOUNDS FOR TREATING CANCER | EVOTEC AG (DE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067067-A1 | COMPOUNDS FOR TREATING CANCER | EVOTEC AG (DE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BCL2, BAX, BCL2A1 | LMNA 2691/4885KMT2A 2214/4885HTT 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.